Highland Private Wealth Management
SLDB icon

Highland Private Wealth Management’s Solid Biosciences SLDB Stock Holding History

Highland Private Wealth Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,956
Closed -$42K – 134
2022
Q3 		$42K Hold
5,956
– – 0.01% 181
2022
Q2 		$55K Buy
+5,956
New +$61.9K 0.01% 185

Other funds holding SLDB

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Camber Capital Management
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
AG
Artal Group Luxembourg $687M AUM 17.07% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highland Private Wealth Management's SLDB Position: Q4 2022 in Review

Highland Private Wealth Management sold out of Solid Biosciences (SLDB) in Q4 2022, closing a stake of 5,956 shares — an estimated $42K sold.

Highland Private Wealth Management first reported a position in SLDB in Q2 2022 and held it in 2 quarters. The position peaked at $55K in Q2 2022. 34 funds tracked by Wall St. Rank hold SLDB as of Q4 2022.

  • Highland Private Wealth Management reported no remaining Solid Biosciences position as of Q4 2022 after selling out during the quarter.
  • Highland Private Wealth Management sold 5,956 Solid Biosciences shares in Q4 2022, an estimated $42K.
  • Highland Private Wealth Management first reported a position in Solid Biosciences in Q2 2022 and held it in 2 quarters.
  • Highland Private Wealth Management's Solid Biosciences position peaked at $55K in Q2 2022.
  • 34 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2022.

Based on Highland Private Wealth Management's 13F filing for Q4 2022.